Patients with rheumatoid arthritis (RA) with synovial lymphocyte aggregates respond better to the anti-tumor necrosis factor (anti-TNF) agent infliximab than those with only diffuse leukocyte infiltration, researchers from the Netherlands report. Reuters Health Information
B cell directed therapy with rituximab may be of some benefit in systemic lupus erythematosus (SLE), researchers report in the December issue of the Annals of the Rheumatic Diseases. Reuters Health Information
Drugs that inhibit tumor necrosis factor provide considerable benefit in treatment of rheumatoid arthritis; however, there is an unmet medical need for alternative therapies. Nature Clinical Practice Rheumatology
